Skip to main content

Table 3 Hazard ratio of PSA recurrence-free survival of established prognostic parameters and BCAR1 expression

From: High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

  Scenario 1 2 3 4
  Analyzable (N) 8522 8662 8778 5362
Preoperative Gleason score biopsy
 3 + 4 vs. ≤3 + 3 1.98 ***    
 4 + 3 vs. 3 + 4 1.62 ***    
 ≥ 4 + 4 vs. 4 + 3 1.30 ***    
Clinical tumor (cT) stage
 T2a vs. T1c 1.33 *** 1.33 ***   
 T2b vs. T2a 1.47 *** 1.40 ***   
 T3a vs. T2c 0.62 * 0.65 *   
Preoperative PSA level
 4–10 vs. <4 1.45 *** 1.38 ** 1.21 * 1.17
 10–20 vs. 4–10 1.52 *** 1.43 *** 1.28 *** 1.19 *
 > 20 vs. 10–20 1.69 *** 1.53 *** 1.20 * 1.19 *
BCAR1 expression
 Weak vs. negative 1.17 * 1.14 1.16 * 1.29 *
 Moderate vs. weak 0.91 0.92 0.88 0.78 *
 Strong vs. moderate 1.14 * 1.08 1.12 1.13
Postoperative Gleason score prostatectomy
 3 + 4 vs. ≤3 + 3   3.05 *** 2.48 *** 2.24 ***
 4 + 3 vs. 3 + 4   2.56 *** 2.13 *** 2.01 ***
 ≥ 4 + 4 vs. 4 + 3   1.70 *** 1.20 * 1.11
Pathological tumor (pT) stage
 T3a vs. T2    2.00 *** 2.03 ***
 T3b vs. T3a    1.72 *** 1.55 ***
 T4 vs. T3b    1.38 * 1.35
Surgical margin (R) status
 R1 vs. R0    1.44 *** 1.31 ***
Lymph node (N) status
 N+ vs. N0     1.44 ***
  1. Scenario 1 combines preoperatively available parameter (preoperative Gleason score obtained on the original biopsy, clinical tumor (cT) stage, and preoperative PSA) with the postoperative BCAR1 expression. In scenario 2 the biopsy Gleason is replaced by the Gleason score obtained on radical prostatectomy (RPE). In scenario 3 cT-stage is superseded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 4 the lymph node (pN) stage is added. Asterisk indicate significance level: * p ≤ 0.05, ** p ≤ 0.001, and *** p ≤ 0.0001